Francis Reed, Jr. is an experienced capital markets professional with extensive fixed income trading, structuring and sales expertise at top-tier investment banks like Morgan Stanley, UBS, Lehman Brothers and Barclays Capital. Presently, Fran is a global regulatory strategist at FactSet Research Systems. Fran is an industry author and speaker on topics including debt capital markets, financial regulatory reform, housing reform and public policy matters. Over his career, Fran has managed institutional trading and sales teams for large complex investors like the U.S. Government Sponsored Enterprises (GSEs), European Supra, Sovereign and Agencies (SSAs), central banks, commercial banks, hedge funds, insurance companies and asset managers.
Fran managed the investment bank resolution “living will” strategy for Morgan Stanley’s massive Title I Plan submission to the Federal Reserve Bank in 2015. Prior to this, Fran was Managing Director and Head of Structured Products, Americas at UBS Investment Bank; Senior Relationship Manager to the GSEs – Fannie Mae, Freddie Mac, Federal Home Loan Banks and Federal Farm Credit Banks and European SSAs at both UBS and Lehman Brothers. Fran managed Lehman Brothers’ structured note sales business and transitioned his team through Lehman’s landmark bankruptcy in 2008 – the largest bankruptcy in U.S. history – over to Barclays Capital. Prior to Lehman Brothers, Fran managed Barclays Capital’s U.S. Agency business in the 1990s and advised Fannie Mae and Freddie Mac in developing their global Benchmark and Reference Note debt programs.
Fran’s education includes an MBA in Finance from Fordham University and a Bachelor of Science in Marketing from Fairfield University. He also holds FINRA Registered Series 7, 63 and 24 and is a Registered Financial Supervisor.
Fran has recently authored several publications on various financial topics including:
Fran lives with his wife and children in New Canaan, CT, where he enjoys rowing, tennis and running with his family. He is Board Member of ClearPharma, a biotech firm and a Founding Board Member of The Children’s Fund for GSD Research, a 501c3 nonprofit charitable organization committed to finding a cure for GSD, a rare genetic condition afflicting their daughter: www.CureGSD.org.
© 2022 Corporate Compliance Insights